Biased Ligands. Better Drugs.


AT1R biased ligand for Acute Heart Failure

TRV027 is a β-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R), and an intravenous drug candidate for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy. On May 16, 2016, we announced that TRV027 failed to meet the primary or secondary endpoints in the BLAST-AHF trial in AHF. Allergan plc (NYSE: AGN) has an exclusive option to license TRV027.

View TRV027 Publications

Copyright © Trevena, Inc.